Verified call record已核验电话会记录 ·
SRPT · Sarepta Therapeutics Q1 FY2026 earnings call record财报电话会记录
Verbatim, receipt-bound excerpts from the earnings-call transcript. This is a source record, not a synthesized analysis or recommendation.来自财报电话会文字记录的原文、可追溯摘录。这是来源记录，不是综合分析或推荐。
12 exact excerpts 条原文摘录
22 numeric receipts 个数值回执
B governed source tier 治理来源层级
Transcript present电话会文本已具备
Call language, kept intact.电话会表述，保持原貌。
The excerpts below are selected from the source record under the bounded evidence policy. Wording is not paraphrased; numbers remain the exact spans captured from the call.以下摘录按受限证据策略从来源记录中选出。文字未被改写；数字保持电话会中捕获的精确片段。
“Turning to gross margin, total cost of sales for the quarter was $109 million, a decrease of 21% compared to last year, driven primarily by lower sales volume.”
Ryan Wong · CFO
claim_5159b1f9b902da7a201b4fa4c6fd3dbcExact numeric spans精确数值片段
109 million21%“In Q1, we reported $400 million of collaboration and other revenues, and consistent with previous guidance, this included $325 million of non-cash collaboration revenue related to Roche declining a program option, as well as $40 million of milestone revenue from the first commercial sale of ELEVIDYS in Japan.”
Ryan Wong · CFO
claim_bd9e12ef7f1fafffd7abb405984448c8Exact numeric spans精确数值片段
400 million325 million40 million
Member evidence layer会员证据层
10 more verified excerpts continue below.条更多已核验摘录在下方继续。
You have the public source preview. Essential and Pro unlock the complete call record, every remaining numeric receipt, and the full audit table—without replacing source language with generated opinion.你正在阅读公开来源预览。Essential 与 Pro 可解锁完整电话会记录、全部剩余数值回执和完整审计表——不会用生成式观点替代来源原文。
2 public excerpts 条公开摘录10 member excerpts 条会员摘录22 total numeric receipts 个数值回执
Inspect the source receipts检查来源回执34 bound spans个已绑定片段
Each available row identifies the source body, transcript segment and byte span used to verify the visible text.每个可用行都标识用于核验可见文本的来源正文、电话会片段和字节范围。
| Claim主张 | Kind类型 | Segment片段 | Byte span字节范围 | Text hash文本哈希 |
|---|---|---|---|---|
claim_bd9e12ef7f1fafffd7abb405984448c8 | quote | 31 | 0–310 | 07a784a390daf8… |
claim_5253da22912fa2c79f72e4aee6fb36c0 | numeric | 31 | 20–31 | 60b4353a3b94a8… |
claim_9329c80961bfc78755653c09eefda962 | numeric | 31 | 123–134 | 4bbb8fe4f6b3fe… |
claim_c24a65d90a6010fb00ee8d292290e55d | numeric | 31 | 226–236 | 848b0a1916da2f… |
claim_5159b1f9b902da7a201b4fa4c6fd3dbc | quote | 31 | 311–470 | 4e4a419f38ed6b… |
claim_93d8af4ed02afce299fcac387d8dec49 | numeric | 31 | 377–388 | a4386cb19907cb… |
claim_e34231412d86dc90fb494cde4b9992d2 | numeric | 31 | 404–407 | 0e69162db740a3… |